EZH2 and acute myeloid leukemia: Specifically, loss of H3K27me at bivalent promoters contributes to enhanced oncogenicity during AML induction, while the same loci remain unaltered during disease maintenance upon targeting EZH2.83 This highlights the importance of understanding the disease stage when designing treatment regimens.